首页> 外文期刊>Midirs midwifery digest >Prospective evaluation of combined local bupivacaine and steroid injections for the management of chronic vaginal and perineal pain
【24h】

Prospective evaluation of combined local bupivacaine and steroid injections for the management of chronic vaginal and perineal pain

机译:对局部布比卡因和类固醇注射液联合治疗慢性阴道和会阴疼痛的前瞻性评估

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Vagmal/permeal pam is common following obstetric trauma or vaginal surgery for prolapse and may have a serious impact on sexual function and quality of life. Local injections of corticosteroids, local anaesthetic and hyaluronidase are treatment options for chronic pain; however, there are no published studies to support their efficacy. The objective of this study was to evaluate prospectively the efficacy of perineal/vaginal injections for chronic localised pain following childbirth or vaginal surgery. Methods: Consecutive women with chronic vaginal/perineal pain were recruited in this prospective series (audit). Pain severity and sexual function were determined using a visual analogue scale (VAS 0-10) and the abbreviated sexual function questionnaire (ASFQ) respectively. Patients underwent local injections with a combination of 0.5% bupivacaine (10 ml), hydrocortisone (100 mg) and hyaluronidase (1,500 IU). Follow-up was undertaken at four-weekly intervals. Further injections were performed as clinically indicated. Results: Fifty-three women underwent >1 injections [mean: 1.86 (range: 1-4)]. Mean interval from index childbirth [43/53 (81%)] or surgical intervention [10/53 (19%)] was 8 months (range 12 weeks-20 years). Twenty-seven women (51%) were sexually active. All reported dyspareunia. Fifteen (28%) women required 1 and 31(59%) two injections. Pre treatment VAS pain scores were 6.1 versus 4.1 after first injection (p = 0.0002, 95% CI 1.01-3.05) and mean ASFQ scores increased from 18.1 to 29.1 (p = 0.01, 95% CI-17.2 to -2.3) 4 weeks post-injection. There were no adverse events or morbidity. 24/27 (89%) sexually active women with dyspareunia resolved and 18/26 (69%) sexually inactive women resumed satisfactory sexual activity 8 weeks post-injection. Conclusion: In our series, this treatment was well tolerated and significant improvements in pain scores and sexual function were observed.
机译:目的:阴道/通透性巴氏杆菌在产科创伤或阴道手术脱垂后很常见,可能严重影响性功能和生活质量。局部注射皮质类固醇激素,局部麻醉药和透明质酸酶是治疗慢性疼痛的选择。但是,尚无发表的研究来支持其疗效。这项研究的目的是前瞻性评估会阴/阴道注射对分娩或阴道手术后慢性局部疼痛的疗效。方法:在本前瞻性研究中(队列)招募了患有慢性阴道/会阴部疼痛的连续女性。分别使用视觉模拟量表(VAS 0-10)和缩写的性功能问卷(ASFQ)确定疼痛的严重程度和性功能。患者接受局部注射0.5%布比卡因(10毫升),氢化可的松(100毫克)和透明质酸酶(1,500 IU)的组合。每四个星期进行一次随访。如临床指示进一步进行注射。结果:53名妇女接受了大于1次的注射[平均:1.86(范围:1-4)]。指数分娩[43/53(81%)]或手术干预[10/53(19%)]的平均间隔为8个月(范围为12周至20岁)。二十七名女性(51%)性活跃。所有报道的性交困难。 15名(28%)妇女需要1和31(59%)两次注射。首次注射后,治疗前VAS疼痛评分分别为6.1和4.1(p = 0.0002,95%CI 1.01-3.05),平均ASFQ评分从4周后的18.1增加到29.1(p = 0.01,95%CI-17.2至-2.3)。 -注射。没有不良事件或发病。注射后8周,有24/27(89%)有性交困难的性活跃​​女性得到解决,而18/26(69%)没有性交的女性恢复了令人满意的性活动。结论:在我们的系列中,该治疗耐受性良好,并且疼痛评分和性功能得到了显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号